Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Vaxxinity, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
09/28/2023 8-K Quarterly results
07/27/2023 8-K Changes in Registrant's Certifying Accountant, Departure of Directors or Certain Officers; Election of Directors; Appointment...
Docs: "U.S. Securities and Exchange Commission 100 F Street, NE",
"Vaxxinity Appoints Peter Powchik, M.D., to Executive Vice President, Global Scientific Director"
02/03/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/24/2022 8-K Quarterly results
03/28/2022 8-K Quarterly results
Docs: "Vaxxinity Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Updates DALLAS, March 24, 2022"
03/21/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Vaxxinity Appoints Dr. Peter Powchik to"
01/04/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "PURSUANT TO SECTION 13 OR",
"Vaxxinity Appoints Jason Pesile"
11/17/2021 8-K Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financi...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report : November 11, 2021 Vaxxinity, Inc. Delaware 001-41058 86-2083865 File Number) Identification No.) 1717 Main St, Ste 338 Dallas, TX, 75201 Registrant's telephone number, including area code: 244-5739 Not applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange...",
"Underwriting Agreement, by and among Vaxxinity, Inc. and BofA Securities, Inc., Jefferies LLC and Evercore Group L.L.C., as representatives of the several underwriters specified therein",
"Amended and Restated Certificate of Incorporation of Vaxxinity, Inc",
"Amended and Restated Bylaws of Vaxxinity, Inc",
"Registration Rights Agreement, by and among Vaxxinity, Inc. and the “Investors,” as defined therein"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy